Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives $55.29 Consensus Price Target from Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $55.2857.

Several analysts have issued reports on KNSA shares. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Finally, Wedbush upped their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $46.31 on Monday. Kiniksa Pharmaceuticals International has a 1-year low of $18.25 and a 1-year high of $49.12. The business has a 50-day moving average price of $43.66 and a 200 day moving average price of $40.54. The company has a market capitalization of $3.54 billion, a P/E ratio of 62.58 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. During the same period last year, the business posted ($0.12) EPS. The company’s revenue for the quarter was up 65.0% on a year-over-year basis. On average, analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares in the company, valued at $692,638.96. This trade represents a 41.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares in the company, valued at $523,082.08. The trade was a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 80,782 shares of company stock valued at $3,458,916. 53.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Virtu Financial LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at about $267,000. Invesco Ltd. lifted its stake in Kiniksa Pharmaceuticals International by 25.9% during the 4th quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock valued at $1,334,000 after acquiring an additional 6,656 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after acquiring an additional 508 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth $51,000. Finally, XTX Topco Ltd purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $291,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.